Skip to main content

Trade-Ideas LLC identified

Anika Therapeutics

(

ANIK

) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Anika Therapeutics as such a stock due to the following factors:

  • ANIK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $4.2 million.
  • ANIK has traded 126,880 shares today.
  • ANIK is trading at 16.05 times the normal volume for the stock at this time of day.
  • ANIK is trading at a new low 12.34% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANIK with the Ticky from Trade-Ideas. See the FREE profile for ANIK NOW at Trade-Ideas

More details on ANIK:

Scroll to Continue

TheStreet Recommends

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. ANIK has a PE ratio of 23. Currently there are 2 analysts that rate Anika Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Anika Therapeutics has been 137,600 shares per day over the past 30 days. Anika has a market cap of $622.7 million and is part of the health care sector and drugs industry. The stock has a beta of 1.99 and a short float of 17.7% with 20.63 days to cover. Shares are up 3.6% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Anika Therapeutics as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 35.8% when compared to the same quarter one year prior, rising from $6.17 million to $8.38 million.
  • ANIK's revenue growth trails the industry average of 29.7%. Since the same quarter one year prior, revenues slightly increased by 7.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ANIK has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 11.62, which clearly demonstrates the ability to cover short-term cash needs.
  • The gross profit margin for ANIKA THERAPEUTICS INC is currently very high, coming in at 82.26%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 35.38% significantly outperformed against the industry average.
  • Net operating cash flow has significantly increased by 81.60% to $8.91 million when compared to the same quarter last year. In addition, ANIKA THERAPEUTICS INC has also vastly surpassed the industry average cash flow growth rate of -2.98%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.